NASDAQ$HSIC
Henry Schein Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported record Q4 2019 financial results from continuing operations.
Henry Schein reported a 7.9% increase in net sales from continuing operations, reaching $2.7 billion. GAAP diluted EPS was $2.25, up 192.2% year-over-year, while non-GAAP diluted EPS was $0.97, a 9.0% increase. The company affirms its 2020 non-GAAP diluted EPS guidance of $3.65 to $3.75.
- GAAP diluted EPS from continuing operations increased by 192.2% year-over-year to $2.25, driven by a net gain on the sale of equity investments.
- Non-GAAP diluted EPS from continuing operations grew by 9.0% year-over-year to $0.97.
- Net sales from continuing operations rose by 7.9% to $2.7 billion, with 8.9% growth in local currencies.
- The company repurchased approximately 2.9 million shares of its common stock during the fourth quarter for $200 million.
Headline financials
Revenue & EPS history
Henry Schein · Revenue · Quarterly
$2.67B
Revenue by segment
Henry Schein · $2.51B total across 2 segments · Q4 2019
- Global Dental$1.72B+2.9%68.6%
- Global Medical$789M+15.2%31.4%
Forward guidance
Henry Schein affirmed 2020 non-GAAP diluted EPS guidance of $3.65 to $3.75, reflecting growth of 4% to 7% compared with 2019.
Tailwinds
- 2020 non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. is expected to be $3.65 to $3.75.
- Guidance assumes no significant supply chain disruption related to the Novel Coronavirus Disease 2019 (COVID-19) for certain infection control products.
- Guidance is for current continuing operations as well as completed or previously announced acquisitions.
- Guidance does not include the impact of potential future acquisitions, if any, and restructuring expenses.
- Guidance assumes foreign exchange rates that are generally consistent with current levels, and that end markets remain stable and are consistent with current market conditions.
Headwinds
- Company is not providing 2020 GAAP diluted EPS guidance.
- Unable to provide an accurate estimate of expenses related to a planned restructuring.
- Restructuring is intended to mitigate stranded costs associated with the spin-off of its Animal Health business.
- Restructuring is intended to drive operating efficiencies.
- Inability to provide these reconciliations is due to the uncertainty and inherent difficulty of predicting the occurrence, the financial impact, and the periods in which the non-GAAP adjustments may be recognized.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.4%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.6%
Avg return
30 days after
45%
31 / 69 earnings
Positive
+11.1%
Q4 2021
Best reaction
-8.5%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -1.6% | +4.6% | |
| Q4 2025 | +5.8% | +2.3% | -8.5% | |
| Q3 2025 | +10.9% | +11.2% | +13.5% | |
| Q1 2025 | +2.0% | +5.1% | +7.8% | |
| Q4 2024 | -2.3% | -7.0% | -10.6% | |
| Q3 2024 | -3.2% | -6.0% | +0.2% | |
| Q2 2024 | -5.4% | -0.9% | +0.4% | |
| Q1 2024 | +6.2% | +7.0% | +0.1% | |
| Q4 2023 | -5.1% | -4.6% | -6.3% | |
| Q3 2023 | +7.5% | +7.3% | +15.5% | |
| Q2 2023 | -2.8% | -1.8% | -5.1% | |
| Q1 2023 | -4.5% | -4.2% | -6.1% | |
| Q4 2022 | -6.2% | -7.5% | -12.8% | |
| Q3 2022 | +1.8% | +6.2% | +21.2% | |
| Q2 2022 | -4.9% | -3.8% | -7.3% | |
| Q1 2022 | +7.4% | +6.6% | +5.6% | |
| Q4 2021 | +11.1% | +10.1% | +14.5% | |
| Q3 2021 | +3.0% | +4.5% | -6.7% | |
| Q2 2021 | -4.8% | -5.2% | -2.3% | |
| Q1 2021 | +6.6% | +8.9% | +5.3% | |
| Q4 2020 | -8.5% | -6.5% | -5.3% | |
| Q3 2020 | -5.0% | -3.0% | +4.6% | |
| Q2 2020 | -5.3% | -4.4% | -6.9% | |
| Q1 2020 | +0.4% | +2.9% | +20.6% | |
| Q4 2019 | -8.4% | -14.4% | -38.9% | |
| Q3 2019 | +4.4% | +4.8% | +5.2% | |
| Q2 2019 | -3.2% | -2.3% | -4.2% | |
| Q1 2019 | +8.6% | +8.9% | +8.6% | |
| Q4 2018 | -5.0% | -5.2% | -5.2% | |
| Q3 2018 | +3.1% | +0.8% | +3.3% | |
| Q2 2018 | -0.5% | -3.6% | +0.5% | |
| Q1 2018 | -6.1% | -4.4% | -6.7% | |
| Q4 2017 | -1.2% | -2.1% | -5.2% | |
| Q3 2017 | -8.5% | -13.6% | -13.0% | |
| Q2 2017 | -7.7% | -7.2% | -4.9% | |
| Q1 2017 | +0.6% | +0.3% | +5.2% | |
| Q4 2016 | +2.7% | +3.2% | +2.0% | |
| Q3 2016 | +4.6% | +6.2% | +1.7% | |
| Q2 2016 | -7.1% | -8.4% | -8.6% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | +7.0% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | -1.9% | — | — | |
| Q1 2015 | -0.4% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | +5.4% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | +0.1% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | +2.1% | — | — | |
| Q4 2012 | -2.2% | — | — | |
| Q3 2012 | -0.6% | — | — | |
| Q2 2012 | +1.8% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | +3.4% | — | — | |
| Q3 2011 | -6.4% | — | — | |
| Q2 2011 | -2.3% | — | — | |
| Q1 2010 | -2.0% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -3.9% | — | — | |
| Q1 2009 | -3.9% | — | — | |
| Q4 2008 | -3.9% | — | — | |
| Q3 2009 | -4.1% | — | — | |
| Q3 2010 | -4.1% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q4 2009 | +2.1% | — | — | |
| Q2 2009 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro